Liquidia (LQDA) Interest & Investment Income (2020 - 2026)
Liquidia (LQDA) posted quarterly Interest & Investment Income of $1.8 million for Q1 2026, up 2.55% year-over-year from $1.7 million in Q1 2025, and up 6.3% quarter-over-quarter from $1.7 million in Q4 2025.
Liquidia (LQDA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Liquidia's Interest & Investment Income history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 2.55% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $6.7 million (down 11.12% YoY), while the FY2025 annual figure was $6.6 million, down 13.46% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.8 million, up from $1.7 million in the prior quarter.
- The five-year high for Interest & Investment Income was $2.1 million in Q4 2024, with the low at $4000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $1.6 million (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 80.95% in 2022, then jumped 22950.0% in 2023.
- Liquidia's Interest & Investment Income stood at $662000.0 in 2022, then surged by 43.2% to $948000.0 in 2023, then jumped by 121.94% to $2.1 million in 2024, then retreated by 20.77% to $1.7 million in 2025, then grew by 6.3% to $1.8 million in 2026.
- Business Quant data shows LQDA's Interest & Investment Income at $1.8 million in Q1 2026, $1.7 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Liquidia | 6.49 Bn | 6.21 Bn | 160.92 Mn | 2.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.48 Mn |
| Mar 31, 2026 | 1.77 Mn |
| Dec 31, 2025 | 1.67 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 948,000.00 |
| Sep 30, 2023 | 862,000.00 |
| Jun 30, 2023 | 734,000.00 |
| Mar 31, 2023 | 922,000.00 |
| Dec 31, 2022 | 662,000.00 |
| Sep 30, 2022 | 359,000.00 |
| Jun 30, 2022 | 65,000.00 |
| Mar 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |